临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)
manual techniques coin toss,118 118
sealed envelopes,115–119 119
Alzheimer’s disease randomization code breaking example,119–120 120
Amendments Clinical Study Protocol,48–50 50
Amino acids characteristics and pharmacological importance,9–11 11
AML see Acute myeloid leukemia Anatomical Therapeutic Chemical (ATC) system,565 565
Antibody drugs origins,7–9 9
Antibody-dependent cell cytotoxicity (ADCC),481,486,498–499 499
APL see Acute promyelocytic leukemia Approval Letter,603 603
Arthritis health-related quality of life,404 404
Asthma immune response,506 506
ductal carcinoma in situ,100–101 101
invasive breast cancer,101 101
lobular carcinoma in situ,100–101 101
time to distant metastasis and prognostic factors in breast cancer gene array,267–268 268
microRNA expression,268 268
Bristol-Myers Co. v. Gonzales,570 570
Bristol-Myers Squibb Co. v. Rhone-Poulenc Rorer Inc,620 620
Capecitabine thymidine phosphorylase as survival biomarker,249 249
Cappuzzo study,245–246 246
Carboplatin Maemondo study,221–224 224
Case Report Form (CRF)follow up reports,446–447 447
writing style,444–445 445
Chronic lymphocytic leukemia (CLL)clinical features,287–288 288